Inhibition of proteasome activity promotes the correct localization of disease-causing α-sarcoglycan mutants in HEK-293 cells constitutively expressing β-, γ-, and δ-sarcoglycan

American Journal of Pathology

Volumn 173, Issue 1, 2008, Pages 170-181

  Gastaldello, Stefano ^a   D'Angelo, Simona ^a   Franzoso, Susanna ^a   Fanin, Marina ^a   Angelini, Corrado ^a   Betto, Romeo ^b,c   Sandonà, Dorianna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

^c Interuniversity Institute of Myology (IIM)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; BETA SARCOGLYCAN; DELTA SARCOGLYCAN; GAMMA SARCOGLYCAN; MUTANT PROTEIN; PROTEASOME;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 46749092995     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.071146     Document Type: Article

References (58)

1. Roberds SL, Leturcq F, Allamand V, Piccolo F, Jeanpierre M, Anderson RD, Lim LE, Lee JC, Tomé FM, Romero NB, Fardeau M, Beckmann JS, Kaplan J-C, Campbell KP: Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994, 78:625-6330
2. Bonnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, McNally EM, Duggan DJ, Angelini C, Hoffmann EP, Ozawa E, Kunkel LM: β-Sarcoglycan mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet 1995, 11:266-273
3. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, Yamamoto H, Bonnemann CG, Gussoni E, Denton PH, Kyriakides T, Middleton L, Hentati F, Ben Hamida V, Nonaka I, Vance JM, Kunkel LM, Ozawa E: Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995, 270:819 -822
4. Nigro V, Moreira EDS, Piluso G, Vainzof M, Belsito A, Politano L, Puca AA, Passos-Bueno MR, Zatz M: Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Nat Genet 1996, 14:195-198
5. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M: Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 2005, 32:563-576
6. Blake DJ, Weir A, Newey SE, Davies K: Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:291-329
7. Pasternak C, Wong S, Elson EL: Mechanical function of dystrophin in muscle cells. J Cell Biol 1995, 128:355-361
8. Lapidos KA, Kakkar R, McNally EM: The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004, 94:1023-1031
9. Boito C, Fanin M, Siciliano G, Angelini C, Pegoraro E: Novel sarcoglycan gene mutations in a large cohort of Italian patients. J Med Genet 2003, 40:e67
10. Moreira ES, Vainzof M, Suzuki OT, Pavanello RC, Zatz M, Passos-Bueno MR: Genotype-phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations. J Med Genet 2003, 40:e12
11. Angelini C, Fanin M, Freda MP, Duggan DJ, Siciliano G, Hoffman EP: The clinical spectrum of sarcoglycanopathies. Neurology 1999, 52:176-179
12. Moore S, Shilling CJ, Westra S, Wall CRN, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, King N, King W, Florence J, Campbell KP, Fenichel GM, Stedman HH, Kissel JT, Griggs RC, Pandya S, Mathews KD, Pestronk A, Serrano C, Darvish D, Mendell JR: Limb-girdle muscular dystrophy in the United States. J Neuropath Exp Neurol 2006, 65:995-1003
13. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP: Progressive muscular dystrophy in α-sarcoglycan-deficient mice. J Cell Biol 1998, 142:1461-1471
14. Hack AA, Groh ME, McNally EM: Sarcoglycans in muscular dystrophy. Microsc Res Tech 2000, 48:167-180
15. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyo-oka T, Hanaoka F: Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997, 94:13873-13878
16. Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, Wakabayashi-Takai E, Noguchi S, Sasaoka T, Ozawa E: Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet 2000, 9:1033-1040
17. Cohn RD, Henry MD, Michele DE, Barresi R, Saito F, Moore S, Flanagan JD, Skwarkchuk MW, Robbins ME, Mendell JR, Williamson RA, Campbell KP: Disruption of Dag1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 2002, 110:639-648
18. Yoshida T, Pan Y, Hanada H, Iwata Y, Shigekawa A: Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J Biol Chem 1998, 273:1583-1590
19. Thompson TG, Chan YM, Hack AA, Brosius M, Rajala M, Lidov HG, McNally EM, Watkins S, Kunkel LM: Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. J Cell Biol 2000, 148:115-126
20. Crosbie RH, Barresi R, Campbell KP: Loss of sarcolemma nNOS in sarcoglycan-deficient muscle. FASEB J 2002, 16:1786-1791
21. Barton ER: Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle. Am J Physiol 2006, 290:C411-C419
22. Betto R, Senter L, Ceoldo S, Tarricone E, Biral D, Salviati G: Ecto-ATPase activity of α-sarcoglycan (adhalin). J Biol Chem 1999, 19:7907-7912
23. Sandonà D, Gastaldello S, Martinello T, Betto R: Characterization of the ATP-hydrolyzing activity of α-sarcoglycan. Biochem J 2004, 381:105-112
24. Sandonà D, Danieli-Betto D, Germinario E, Biral D, Martinello T, Gastaldello S, Betto R: The T-tubule membrane ATP-operated P2X4 receptor influences contractility of skeletal muscle. FASEB J 2005, 19:1184-1186
25. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, Hadhazy MA, Hadhazy MR, Sweeney HL, McNally EM: Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J Cell Sci 2000, 113:2535-2544
26. Noguchi S, Wakabayashi E, Imamura M, Yoshida M, Ozawa E: Formation of sarcoglycan complex with differentiation in cultured myocytes. Eur J Biochem 2000, 267:640-648
27. Jung D, Duclos F, Apostol B, Straub V, Lee JC, Allamand V, Venzke DP, Sunada Y, Moomaw CR, Leveille CJ, Slaughter CA, Crawford TO, McPherson JD, Campbell KP: Characterization of δ-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy. J Biol Chem 1996, 271:32321-32329
28. Zhu X, Hadhazy M, Groh ME, Wheeler MT, Wollmann R, McNally EM: Over-expression of γ-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of sarcoglycan assembly. J Biol Chem 2001, 276:21785-21790
29. Chan YM, Bonnemann CG, Lidow HGW, Kunkel LM: Molecular organization of sarcoglycan complex in mouse myotubes in culture. J Cell Biol 1998, 143:2033-2044
30. Shi W, Chen Z, Schottenfeld J, Stahl RC, Kunkel LM, Chan YM: Specific assembly pathway of sarcoglycans is dependent on β- and δ-sarcoglycan. Muscle Nerve 2004, 29:409-419
31. Chen J, Shi W, Zhang Y, Sokol R, Cai H, Lun M, Moore BF, Farber MJ, Stepanchick JS, Bonnemann CG, Chan YM: Identification of functional domains in sarcoglycans essential for their interaction and plasma membrane targeting. Exp Cell Res 2006, 312:1610-1625
32. Vainzof M, Passos-Bueno MR, Pavanello RC, Marie SK, Oliveira AS, Zatz M: Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. J Neurol Sci 1999, 164:44-49
33. Meena AK, Sreenivas D, Sundaram C, Rajasekhar R, Sita JS, Borgohain R, Suvarna A, Kaul S: Sarcoglycanopathies: a clinico-pathological study. Neurol India 2007, 55:117-121
34. Lo HP, Cooper ST, Evesson FJ, Seto JT, Chiotis M, Tay V, Compton AG, Cairns AG, Corbett A, MacArthur DG, Yang N, Reardon K, North KN: Limb-girdle muscular dystrophy: diagnostic evaluation, frequency and clues to pathogenesis. Neuromuscul Disord 2008, 18:34-44
35. Guglieri M, Magri F, D'Angelo MG, Prelle A, Morandi L, Rodolico C, Cagliani R, Mora M, Fortunato F, Bordoni A, Del Bo R, Ghezzi S, Pagliarani S, Lucchiari S, Salani S, Zecca C, Lamperti C, Ronchi D, Aguennouz M, Ciscato P, Di Blasi C, Ruggieri A, Moroni I, Turconi A, Toscano A, Moggio M, Bresolin N, Comi GP: Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008, 29:258-266
36. Carrie A, Piccolo F, Leturcq F, de Toma C, Azibi K, Beldjord C, Vallat JM, Merlini L, Voit T, Sewry C, Urtizberea JA, Romero N, Tomè FM, Fardeau M, Sunada Y, Campbell KP, Kaplan JC, Jeanpierre M: Mutational diversity and hot spots in the α-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). J Med Genet 1997, 34:470-475
37. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C: Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 1997, 336:618-624
38. Trabelsi M, Kavian N, Daoud F, Commere V, Deburgrave N, Beugnet C, Llense S, Barbot JC, Vasson A, Kaplan JC, Leturcq F, Chelly J: Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet 2008, [Epub ahead of print]
39. Fokkema IF, den Dunnen JT, Taschner PE: LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach. Human Mutat 2005, 26:63-68
40. Holt KH, Campbell KP: Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem 1998, 273:34667-34670
41. Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899
42. Ward CL, Omura S, Kopito RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995, 83:121-127
43. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990, 63:827-834
44. Esapa CT, McIlhinney RA, Blake DJ: Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells. Hum Mol Genet 2005, 14:295-305
45. Esapa CT, Waite A, Locke M, Benson MA, Krauss M, McIlhinney RA, Sillitoe RV, Beesley PW, Blake DJ: SGCE missense mutations that cause myoclonus-dystonia syndrome impair ε-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum Mol Genet 2007, 16:327-342
46. Kumamoto T, Fujimoto S, Ito T, Horinouchi H, Ueyama H, Tsuda T: Proteasome expression in the skeletal muscles of patients with muscular dystrophy. Acta Neuropathol Berl 2000, 100:595-602
47. Abu-Baker A, Messaed C, Laganiere J, Gaspar C, Brais B, Rouleau GA: Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003, 12:2609-2623
48. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP: Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am J Pathol 2003, 163:1663-1675
49. Bonucelli G, Sotgia F, Capozza F, Gazzero E, Minetti C, Lisanti MP: Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice. Cell Cycle 2007, 6:1242-1248
50. Assereto S, Stringara S, Sotgia F, Bonuccelli G, Broccolini A, Pedemonte M, Traverso M, Biancheri R, Zara F, Bruno C, Lisanti MP, Minetti C: Pharmaceutical rescue of the dystrophin complex in Duchenne and Becker skeletal muscle explants by proteasomal inhibitor treatment. Am J Physiol 2006, 290:C577-C582
51. Draviam RA, Wang B, Shand SH, Xiao X, Watkins SC: α-Sarcoglycan is recycled from the plasma membrane in the absence of sarcoglycan complex assembly. Traffic 2006, 7:1-18
52. Shiga K, Yoshioka H, Matsumiya T, Kimura I, Takeda S, Imamura M: ζ-Sarcoglycan is a functional homologue of γ-sarcoglycan in the formation of the sarcoglycan complex. Exp Cell Res 2006, 312:2083-2092
53. Esapa CT, Bentham GR, Schroder JE, Kroger S, Blake DJ: The effects of post-translational processing on dystroglycan synthesis and trafficking. FEBS Lett 2003, 555:209-216
54. Ellgaard L, Helenius A: Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003, 4:181-191
55. Kisselev A, Goldberg A: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758
56. Bernier V, Lagace M, Bichet DG, Bouvier M: Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 2004, 15:222-228
57. Galbiati F, Volonte D, Minetti C, Bregman DB, Lisanti MP: Limbgirdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutant and rescues wild-type caveolin-3. J Biol Chem 2000, 275:37702-37711
58. Chaudhuri TK, Paul S: Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J 2006, 273:1331-1349